Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    October 2018
  1. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    PubMed     Text format     Abstract available


  2. OSAWA M, Imamura M, Teraoka Y, Uchida T, et al
    Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    J Gastroenterol. 2018 Oct 17. pii: 10.1007/s00535-018-1520.
    PubMed     Text format     Abstract available


    September 2018
  3. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Text format     Abstract available


    July 2018
  4. SUDA G, Kurosaki M, Itakura J, Izumi N, et al
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. pii: 10.1007/s00535-018-1495.
    PubMed     Text format     Abstract available


  5. MAEKAWA S, Enomoto N
    The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
    J Gastroenterol. 2018 Jul 6. pii: 10.1007/s00535-018-1493.
    PubMed     Text format    


    May 2018
  6. TOYODA H, Atsukawa M, Takaguchi K, Senoh T, et al
    Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2018 May 8. pii: 10.1007/s00535-018-1473.
    PubMed     Text format     Abstract available


    April 2018
  7. TSUJI K, Kurosaki M, Itakura J, Mori N, et al
    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Gastroenterol. 2018 Apr 6. pii: 10.1007/s00535-018-1455.
    PubMed     Text format     Abstract available


    March 2018
  8. AKUTA N, Toyota J, Karino Y, Ikeda F, et al
    Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    J Gastroenterol. 2018 Mar 2. pii: 10.1007/s00535-018-1445.
    PubMed     Text format     Abstract available


    January 2018
  9. ZEUZEM S, Serfaty L, Vierling J, Cheng W, et al
    The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    J Gastroenterol. 2018 Jan 17. pii: 10.1007/s00535-018-1429.
    PubMed     Text format     Abstract available


  10. SUDA G, Ogawa K, Morikawa K, Sakamoto N, et al
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 Jan 3. pii: 10.1007/s00535-017-1427.
    PubMed     Text format     Abstract available


    November 2017
  11. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Nov 13. doi: 10.1007/s00535-017-1409.
    PubMed     Text format     Abstract available


  12. MAEKAWA S, Sato M, Kuratomi N, Inoue T, et al
    Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1405.
    PubMed     Text format     Abstract available


    October 2017
  13. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Oct 20. doi: 10.1007/s00535-017-1396.
    PubMed     Text format     Abstract available


  14. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Text format     Abstract available


    September 2017
  15. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available


    August 2017
  16. KAWAKAMI Y, Ochi H, Hayes CN, Imamura M, et al
    Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    J Gastroenterol. 2017 Aug 16. doi: 10.1007/s00535-017-1380.
    PubMed     Text format     Abstract available


    May 2017
  17. MIZUOCHI T, Takano T, Yanagi T, Ushijima K, et al
    Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.
    J Gastroenterol. 2017 May 31. doi: 10.1007/s00535-017-1351.
    PubMed     Text format     Abstract available


  18. SUDA G, Furusyo N, Toyoda H, Kawakami Y, et al
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2017 May 30. doi: 10.1007/s00535-017-1353.
    PubMed     Text format     Abstract available


    January 2017
  19. UEDA Y, Ikegami T, Akamatsu N, Soyama A, et al
    Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2017 Jan 30. doi: 10.1007/s00535-017-1310.
    PubMed     Text format     Abstract available


    December 2016
  20. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Text format     Abstract available


  21. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  22. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  23. MORIO K, Imamura M, Kawakami Y, Nakahara T, et al
    ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  24. TAKEDA H, Takai A, Inuzuka T, Marusawa H, et al
    Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  25. MORIO R, Imamura M, Kawakami Y, Morio K, et al
    Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  26. KAWAI-KITAHATA F, Asahina Y, Tanaka S, Kakinuma S, et al
    Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: